Bronchogen 20mg

1. 1

   Clean the rubber stoppers of both the Bronchogen vial and bacteriostatic water vial using sterile alcohol prep pads and permit them to air-dry completely.

2. 2

   Draw exactly 3.0 mL of bacteriostatic water into a clean reconstituting syringe.

3. 3

   Insert the needle at a slight angle through the vial septum, aiming the stream along the internal glass wall to prevent turbulent impact on the lyophilized powder.

4. 4

   Allow the diluent to fully hydrate the peptide cake for approximately 30 to 60 seconds without agitating.

5. 5

   Gently rotate and roll the vial between the palms until the solution is completely dissolved and transparent; do not shake or introduce foam.

6. 6

   Confirm the reconstituted solution is clear, free of visible particles, and immediately place it in refrigerated storage at 2–8°C.

Overview

Bronchogen is a synthetic tetrapeptide consisting of the amino acid sequence Ala-Glu-Asp-Leu (AEDL). Originating from the Russian bioregulator peptide research framework established by Vladimir Khavinson, this compound is specifically categorized as an airway and bronchial epithelium-targeted regulator. Scientific literature indicates that these low-molecular-weight peptides were developed to mimic the biological signals of native organ extracts, aiming to modulate tissue-specific cellular functions. Preclinical assessments in animal models and cell cultures suggest that Bronchogen influences the morphofunctional characteristics of respiratory tissues. In rodent models of experimental chronic obstructive pulmonary conditions, the peptide was reported to attenuate pathological airway remodeling and modulate inflammatory markers. In vitro experiments using bronchial epithelial cultures have demonstrated changes in differentiation markers and cellular proliferation, particularly in aged or stressed tissues. Despite its presence in specialized laboratory research and scientific publications, Bronchogen has not undergone human clinical trials and possesses no therapeutic approvals from regulatory authorities. All experimental data remain confined to non-clinical laboratory models, organotypic explants, and cell culture studies, where it serves primarily as a molecular probe for investigating peptide-nucleic acid interactions and respiratory cell biology.

1. 1.Kuzubova et al., Bulletin of Experimental Biology and Medicine, 2015 — Modulating effect of peptide therapy on bronchial epithelium in rats with obstructive lung pathology
2. 2.Titova et al., Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova, 2017 — Anti-inflammatory and regenerative effect of peptide therapy in a model of obstructive lung pathology
3. 3.Khavinson et al., Bulletin of Experimental Biology and Medicine, 2012 — Tissue-specific stimulation of cell differentiation during aging by synthetic peptides
4. 4.Zakutskii et al., Advances in Gerontology, 2006 — Tissue-specific effects of synthetic bioregulators in young and old rat organotypic cultures
5. 5.Fedoreyeva et al., Biochemistry (Moscow), 2011 — Nuclear penetration of short peptides and interaction with DNA sequences in HeLa cells
6. 6.Monaselidze et al., Bulletin of Experimental Biology and Medicine, 2011 — Effect of the peptide Bronchogen on DNA thermostability and melting temperature
7. 7.Fedoreyeva et al., Biochemistry (Moscow), 2017 — Regulation of gene expression by exogenous short peptides in Nicotiana tabacum cultures
8. 8.Avolio et al., International Journal of Molecular Sciences, 2022 — Distinguishing synthetic bronchial bioregulators and inflammatory pathways in monocyte cultures
9. 9.Khavinson, Neuroendocrinology Letters, 2002 — Theoretical foundations and history of short peptide bioregulators in aging

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.